<?xml version="1.0" encoding="UTF-8"?>
<p>Although CAR T-cell therapy may impart some additional infectious risk not explained by the patient's backdrop of prior cancer treatment, it was not possible to quantify the attributable risk, in part owing to the difficulty of selecting an appropriate comparison group for this highly customized patient cohort participating in a phase I clinical trial. Because this was a single-center study, the epidemiology of infections along with susceptibility patterns may differ from that in other centers and thus may affect how one's institution will approach antimicrobial prophylaxis.</p>
